Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.

Thapa B, Kc R, Bahniuk M, Schmitke J, Hitt M, Lavasanifar A, Kutsch O, Seol DW, Uludag H.

Hum Gene Ther. 2019 Oct 29. doi: 10.1089/hum.2019.096. [Epub ahead of print]

PMID:
31547718
2.

Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Fernandes JP, Cristi F, Eaton HE, Chen P, Haeflinger S, Bernard I, Hitt MM, Shmulevitz M.

J Virol. 2019 Oct 29;93(22). pii: e01380-19. doi: 10.1128/JVI.01380-19. Print 2019 Nov 15.

PMID:
31462562
3.

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.

Ganesan A, Ahmed M, Okoye I, Arutyunova E, Babu D, Turnbull WL, Kundu JK, Shields J, Agopsowicz KC, Xu L, Tabana Y, Srivastava N, Zhang G, Moon TC, Belovodskiy A, Hena M, Kandadai AS, Hosseini SN, Hitt M, Walker J, Smylie M, West FG, Siraki AG, Lemieux MJ, Elahi S, Nieman JA, Tyrrell DL, Houghton M, Barakat K.

Sci Rep. 2019 Aug 27;9(1):12392. doi: 10.1038/s41598-019-48826-6.

4.

RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line.

Chen H, Crosley P, Azad AK, Gupta N, Gokul N, Xu Z, Weinfeld M, Postovit LM, Pangas SA, Hitt MM, Fu Y.

Int J Mol Sci. 2019 Jul 15;20(14). pii: E3471. doi: 10.3390/ijms20143471.

5.

Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.

Irwin CR, Hitt MM, Evans DH.

Front Oncol. 2017 Sep 26;7:229. doi: 10.3389/fonc.2017.00229. eCollection 2017. Review.

6.

Traceable PEO-poly(ester) micelles for breast cancer targeting: The effect of core structure and targeting peptide on micellar tumor accumulation.

Garg SM, Paiva IM, Vakili MR, Soudy R, Agopsowicz K, Soleimani AH, Hitt M, Kaur K, Lavasanifar A.

Biomaterials. 2017 Nov;144:17-29. doi: 10.1016/j.biomaterials.2017.08.001. Epub 2017 Aug 4.

7.

Assessment of Specificity of an Adenovirus Targeted to HER3/4.

MacLeod SH, Potts KG, Chaurasiya S, Hitt MM.

Methods Mol Biol. 2017;1652:275-293. doi: 10.1007/978-1-4939-7219-7_18.

PMID:
28791648
8.

Polyoxovanadate-Alkoxide Clusters as a Redox Reservoir for Iron.

Li F, Carpenter SH, Higgins RF, Hitt MG, Brennessel WW, Ferrier MG, Cary SK, Lezama-Pacheco JS, Wright JT, Stein BW, Shores MP, Neidig ML, Kozimor SA, Matson EM.

Inorg Chem. 2017 Jun 19;56(12):7065-7080. doi: 10.1021/acs.inorgchem.7b00650. Epub 2017 May 26.

PMID:
28548499
9.

Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.

Potts KG, Irwin CR, Favis NA, Pink DB, Vincent KM, Lewis JD, Moore RB, Hitt MM, Evans DH.

EMBO Mol Med. 2017 May;9(5):638-654. doi: 10.15252/emmm.201607296.

10.

Novel High-throughput Approach for Purification of Infectious Virions.

James KT, Cooney B, Agopsowicz K, Trevors MA, Mohamed A, Stoltz D, Hitt M, Shmulevitz M.

Sci Rep. 2016 Nov 9;6:36826. doi: 10.1038/srep36826.

11.

Numeracy and the Persuasive Effect of Policy Information and Party Cues.

Mérola V, Hitt MP.

Public Opin Q. 2016 Summer;80(2):554-562. Epub 2015 Dec 31.

12.

Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.

Chaurasiya S, Hew P, Crosley P, Sharon D, Potts K, Agopsowicz K, Long M, Shi C, Hitt MM.

Cancer Gene Ther. 2016 Jun;23(6):178-87. doi: 10.1038/cgt.2016.18. Epub 2016 May 6.

PMID:
27151235
13.

Synthesis and evaluation of glycopolymeric decorated gold nanoparticles functionalized with gold-triphenyl phosphine as anti-cancer agents.

Adokoh CK, Quan S, Hitt M, Darkwa J, Kumar P, Narain R.

Biomacromolecules. 2014 Oct 13;15(10):3802-10. doi: 10.1021/bm5010977. Epub 2014 Sep 10.

PMID:
25162942
14.

Comparing efficiency of micro-RNA and mRNA biomarker liberation with microbubble-enhanced ultrasound exposure.

Forbrich A, Paproski R, Hitt M, Zemp R.

Ultrasound Med Biol. 2014 Sep;40(9):2207-16. doi: 10.1016/j.ultrasmedbio.2014.05.005. Epub 2014 Jul 9.

PMID:
25023097
15.

RNA biomarker release with ultrasound and phase-change nanodroplets.

Paproski RJ, Forbrich A, Hitt M, Zemp R.

Ultrasound Med Biol. 2014 Aug;40(8):1847-56. doi: 10.1016/j.ultrasmedbio.2014.01.011. Epub 2014 May 2.

PMID:
24792584
16.

Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice.

Benesch MG, Tang X, Maeda T, Ohhata A, Zhao YY, Kok BP, Dewald J, Hitt M, Curtis JM, McMullen TP, Brindley DN.

FASEB J. 2014 Jun;28(6):2655-66. doi: 10.1096/fj.13-248641. Epub 2014 Mar 5.

PMID:
24599971
17.

Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Irwin CR, Favis NA, Agopsowicz KC, Hitt MM, Evans DH.

PLoS One. 2013 Dec 31;8(12):e84134. doi: 10.1371/journal.pone.0084134. eCollection 2013.

18.

Diglycolic acid inhibits succinate dehydrogenase activity in human proximal tubule cells leading to mitochondrial dysfunction and cell death.

Landry GM, Dunning CL, Conrad T, Hitt MJ, McMartin KE.

Toxicol Lett. 2013 Aug 29;221(3):176-84. doi: 10.1016/j.toxlet.2013.06.231. Epub 2013 Jul 1.

PMID:
23827505
19.

2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.

Sharon D, Schümann M, MacLeod S, McPherson R, Chaurasiya S, Shaw A, Hitt MM.

PLoS One. 2013 Jun 4;8(6):e65222. doi: 10.1371/journal.pone.0065222. Print 2013.

20.

Microbubble-enhanced ultrasound liberation of mRNA biomarkers in vitro.

Forbrich A, Paproski R, Hitt M, Zemp R.

Ultrasound Med Biol. 2013 Jun;39(6):1087-93. doi: 10.1016/j.ultrasmedbio.2012.12.015. Epub 2013 Apr 3.

PMID:
23562017
21.

Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.

Desilva A, Wuest M, Wang M, Hummel J, Mossman K, Wuest F, Hitt MM.

Am J Nucl Med Mol Imaging. 2012;2(1):88-98. Epub 2011 Dec 15.

22.

HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.

MacLeod SH, Elgadi MM, Bossi G, Sankar U, Pisio A, Agopsowicz K, Sharon D, Graham FL, Hitt MM.

Cancer Gene Ther. 2012 Dec;19(12):888-98. doi: 10.1038/cgt.2012.79. Epub 2012 Oct 26.

PMID:
23099884
23.

Oncolytic viruses in the treatment of bladder cancer.

Potts KG, Hitt MM, Moore RB.

Adv Urol. 2012;2012:404581. doi: 10.1155/2012/404581. Epub 2012 Jul 29.

24.

Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma.

Gelebart P, Hegazy SA, Wang P, Bone KM, Anand M, Sharon D, Hitt M, Pearson JD, Ingham RJ, Ma Y, Lai R.

Blood Cancer J. 2012 Aug 10;2:e82. doi: 10.1038/bcj.2012.27.

25.

The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.

Wang P, Zhang JD, Wu F, Ye X, Sharon D, Hitt M, McMullen TP, Hegazy SA, Gelebart P, Yang J, Ma Y, Lai R.

Cell Signal. 2012 Oct;24(10):1955-63. doi: 10.1016/j.cellsig.2012.06.005. Epub 2012 Jun 26.

PMID:
22743134
26.

A multi-institutional study evaluating the diagnostic utility of the spec cPL™ and SNAP® cPL™ in clinical acute pancreatitis in 84 dogs.

McCord K, Morley PS, Armstrong J, Simpson K, Rishniw M, Forman MA, Biller D, Parnell N, Arnell K, Hill S, Avgeris S, Gittelman H, Moore M, Hitt M, Oswald G, Marks S, Burney D, Twedt D.

J Vet Intern Med. 2012 Jul-Aug;26(4):888-96. doi: 10.1111/j.1939-1676.2012.00951.x. Epub 2012 Jun 7.

27.

Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.

Zhang J, Wang P, Wu F, Li M, Sharon D, Ingham RJ, Hitt M, McMullen TP, Lai R.

Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.

PMID:
22155737
28.

Fungal myelitis caused by Phialosimplex caninus in an immunosuppressed dog.

Armstrong PF, Sigler L, Sutton DA, Grooters AM, Hitt M.

Med Mycol. 2012 Jul;50(5):509-12. doi: 10.3109/13693786.2011.633106. Epub 2011 Nov 28.

PMID:
22122265
29.

Tyrosinase as a dual reporter gene for both photoacoustic and magnetic resonance imaging.

Paproski RJ, Forbrich AE, Wachowicz K, Hitt MM, Zemp RJ.

Biomed Opt Express. 2011 Mar 2;2(4):771-80. doi: 10.1364/BOE.2.000771.

30.

America at the energy crossroads.

Hitt MA.

Conserv Biol. 2007 Apr;21(2):293-4. No abstract available.

PMID:
17391177
31.

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB.

J Gen Virol. 2006 Mar;87(Pt 3):641-50.

PMID:
16476986
33.

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.

Xing Z, Santosuosso M, McCormick S, Yang TC, Millar J, Hitt M, Wan Y, Bramson J, Vordermeier HM.

Curr Gene Ther. 2005 Oct;5(5):485-92. Review.

PMID:
16250889
34.

Transcriptionally targeted adenovirus vectors.

Sadeghi H, Hitt MM.

Curr Gene Ther. 2005 Aug;5(4):411-27. Review.

PMID:
16101515
36.

Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.

Gabaglia CR, Sercarz EE, Diaz-De-Durana Y, Hitt M, Graham FL, Gauldie J, Braciak TA.

Vaccine. 2004 Nov 25;23(2):247-57.

PMID:
15531044
37.

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.

Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z.

J Immunol. 2004 Nov 15;173(10):6357-65.

39.

Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth.

Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP.

Oncogene. 2004 Jul 22;23(33):5632-42.

PMID:
15184878
40.

Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.

Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM.

J Immunol. 2004 Apr 1;172(7):4535-44.

41.
42.

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK.

Cancer Gene Ther. 2003 Oct;10(10):755-63.

PMID:
14502228
43.
45.

Challenges and strategies for cystic fibrosis lung gene therapy.

Koehler DR, Hitt MM, Hu J.

Mol Ther. 2001 Aug;4(2):84-91. Review.

46.

Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.

Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK.

Cancer Gene Ther. 2001 May;8(5):361-70.

47.

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study.

Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK.

Leukemia. 2001 May;15(5):846-54.

49.
50.

Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.

Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J.

Gene Ther. 2001 Feb;8(4):282-90.

Supplemental Content

Support Center